Insufficient activity of the bone-forming osteoblasts leads to low bone mass and predisposes to fragility fractures. The functional capacity of mesenchymal stem cells (hMSCs), the precursors of osteoblasts, may be compromised in elderly individuals, in relation with the epigenetic changes associated with aging. However, the role of hMSCs in the pathogenesis of osteoporosis is still unclear.
INTRODUCTION
Osteoporotic hip fractures have a particularly negative impact on the patients' quality of life and life expectancy. The pathogenetic mechanisms of osteoporosis are not completely understood, but they imply an imbalance in bone remodelling, with a predominance of bone resorption over bone formation. Osteoblasts are the cells responsible for bone formation. Human mesenchymal stem cells (hMSCs) are pluripotent cells capable of differentiating into osteoblasts, chondrocytes, adipocytes and myoblasts. Therefore, hMSCs are the subject of considerable interest from a double perspective. On the one hand, hMSC malfunction may be involved in the pathogenesis of osteoporosis 1, 2 . Thus, elucidating the mechanisms involved in hMSCs proliferation and differentiation could point to new drug targets to improve osteoblast function in osteoporotic patients. On the other hand, the infusion of hMSCs could theoretically improve bone formation systemically or locally. A few studies tried to characterize hMSCs from patients with osteoporosis, but the results are controversial [3] [4] [5] . Therefore, much more basic research is needed to characterize hMSCs in osteoporosis prior to use them for the treatment of skeletal disorders.
Epigenetic mechanisms play an important role in skeletal biology. In particular, DNA methylation has been shown to modulate the differentiation of cells towards the osteoblastic lineage 6, 7 . Thus, it is tempting to speculate that changes in DNA methylation influence the differentiation capability of hMSCs in osteoporosis. However there are only scarce data about the methylation signature of skeletal hMSCs. Therefore, we aimed to perform a genome-wide methylome analysis of hMSCs from patients with hip fractures and explore the functional consequences at the transcriptome level and the ability to proliferate and differentiate in vitro. 4 
RESULTS

Isolation and characterization of hMSCs
We had similar success rate in establishing an hMSC culture with samples obtained from patients with fractures (27 out of 41, 66%) or with OA (22 out of 32, 69%). The hMSC phenotype was confirmed by flow cytometry using a combination of markers (CD45 (Table 1 and Supplemental Fig. S4 ).
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Differential methylated sites were enriched in enhancers regions (which included 2425 of the 9038 differentially methylated CpGs). The distances to the transcription start sites (TSSs) are shown in Supplemental Figure S5 . The region level analysis revealed 1684 differential methylated gene enhancer regions; 870 regions (associated with 722 protein-coding genes) were hypermethylated and 814 (678 genes) were hypomethylated in FRX in comparison with OA (Supplemental Table S1 and Figure 1A ). Most FRX and OA samples tended to be grouped in common clusters, but there was some degree of overlapping, as shown in Fig. 1B . Genes with differentially-methylated enhancers were overrepresented among pathways related to stem cell development and bone-related pathways, like the Wnt receptor signaling pathway (p=4.5x10 -8 binomial test), regulation of osteoblast differentiation (p=9.1x10 -5 ), regulation of hMSCs proliferation (p=7.6x10 -6 ) and bone mineralization (p=7.6x10 
Gene expression analysis
Overall, 11390 genes were expressed in both FRX and OA samples, whereas 496 genes were expressed only in FRX and 1695 in OA. As expected, the gene expression signature was typical of hMSCs (Supplemental Table S2 ). Overall, 99 protein-coding genes were up-regulated in FRX (FDR<0.10 and fold-change>2), whereas 239 were down-regulated (Supplemental Fig. S7 and Supplemental Table S3 ). The top 50 up-or down-regulated genes are shown in Tables 2 and 3. Among genes with differential expression, those up-regulated in FRX were enriched in pathways related to hMSCs differentiation and bone formation, whereas those down-regulated in FRX were enriched in pathways related to the immune response, among others (Supplemental Table S4 ).
Correlation between differential DNA methylation and differential gene expression 6 Genes with differentially methylated enhancers were overrepresented among those showing differential expression (19.8% versus 9.2% in those without differential expression; p=1.2x10 -10 ). The direction of the association was variable, but there was a trend for an inverse correlation between enhancer methylation and expression (Odds Ratio [OR] 0.3; 95% confidence interval 0.12-0.99; p=0.05). This is schematically depicted in Fig. 2A, showing that 18 
Validation of expression and methylation differences across groups
We confirmed, by qPCR, the expression pattern of 10 Figure S12) . 7 We studied the DNA methylation aging in our samples by using a software based on Illumina DNA Infinium 450K data that analyses a set of genes showing age-related changes in methylation. There was a significant correlation between the epigenetic age and the chronological age (r=0.64, p=1.357e-05). The slopes of the regression lines were similar in both patient groups (Figure 3, left panel) , but the lines were vertically displaced. Therefore, when the regression was computed with both groups combined, the deviations of the epigenetic age from the chronological age were higher in the FRX group than in the OA group, thus suggesting accelerated epigenetic aging in the former (Fig. 3, right panel).
DNA methylation age
Proliferative capability of hMSCs
Interestingly, the proportion of actively-dividing, Ki-67 positive cells was significantly higher among hMSCs grown from patients with FRX ( Figure 4A ). These results agreed with those obtained from a MTT assay, which confirmed a higher proliferation rate in hMSCs cultures established from patients with fractures ( Figure 4B ).
Transcriptional signature and bone differentiation capacity of hMSCs
Analysis of the gene expression levels of a set of osteogenic and adipogenic markers showed significant differences in the expression levels of key osteogenic genes ( Figure 4C ), such as OSX, ALPL, SPP1 and BGLAP, between patients with osteoporotic fractures and OA. These data agreed and validated the previously shown results from the RNAseq analysis. Interestingly, OSX, a key transcription factor expressed in the first stages of osteoblast development was significantly upregulated in hMSCs from patients with FRX whereas collagen expression was similar in both groups.
Markers, such as ALPL and SPP1, normally expressed later on during the osteogenic differentiation process, were down-regulated in hMSCs isolated from patients with osteoporotic fractures. On the 8 other hand, adipogenic markers, such as PPARG and LPL, were expressed less abundantly in patients with fractures than in those with OA ( Fig. 4C ).
In line with their hMSC phenotype, the cells were able to differentiate normally into adipocytes and osteoblasts (Fig. 5A) . However, there were marked differences between groups and the capacity to form a mineralized matrix was markedly diminished in hMSCs from patients with FRX (p=0.00015; Fig. 5B ). The alkaline phosphatase activity in hMSC cultures from FRX was also much lower than in cultures of OA origin (Fig. 5C) , and there was a correlation between alkaline phosphatase activity and matrix mineralization (Spearman's rho 0.84, p<0.001). On the other hand, there was a tendency for enhanced OSX and RUNX2 expression in FRX cells (Fig. 5D ).
DISCUSSION
We have previously shown that modifications in DNA methylation play a central role in the differentiation of cells along the osteoblastic lineage and that genes related to skeletal development are differentially methylated in bone samples of patients with osteoporotic fractures 8 . In the present study, we explored the epigenome of hMSCs in patients with fractures. To our knowledge, this is the first study combining epigenome-wide and transcriptome-wide analyses of hMSCs in osteoporosis. We established that the methylation signatures of hMSCs from patients with fractures and OA show significant differences at the enhancer regions of a number of genes related to cell proliferation and differentiation.
Our study has some limitations. The method used does not allow distinguishing methylated and hydoxymethylated cytosines. Due to practical reasons, we isolated hMSCs from the bone marrow of OA patients rather than normal bone marrow as comparison controls. Nevertheless, it has been suggested that MSCs from OA patients have similar proliferation and osteogenic differentiation 9 capacity to MSCs from healthy donors 9 . Also, we removed the subchondral region, thus trying to avoid the potential influence of the changes taking place in the subchondral bone 10 . Aging is associated with methylation differences in some genes 11 and patients with fractures were somewhat older than those with OA. Nevertheless, we adjusted the results including age as a covariate to avoid any age-related bias. Also, due to the low percentage of hMSCs in bone marrow (less than 1/10,000 to 1/100,000) hMSCs needed to be expanded in vitro prior to the analysis. However, to avoid changes in the epigenome signature that could bias the results, in vitro expansion was kept to a minimum and only cells at first passage were used for the analyses.
The classical view of DNA methylation tended to associate increased methylation with decreased gene expression and vice versa. However, our results confirm that the relationship between methylation and expression is indeed variable. Although increased methylation was associated with a decreased expression of many genes, the opposite was also true. In fact, that seems to be the case in other cell types 12, 13 . Additionally, as previously reported in other conditions, including the osteoarthritic cartilage 14, 15 , most differentially methylated regions do not appear to be at the gene bodies or at promoter regions, but at genomic regions with enhancer activity distant from the promoter. Thus, changes in methylation at regulatory regions may influence the expression of genes situated several hundred kilobases away. Also, as shown in our genomic region analysis, most regions showing differential methylation between groups appear to be outside CpG islands. MSCs from fracture patients showed an up-regulation of the genes driving osteogenic differentiation, such as RUNX2 and OSX. The expression of some genes such as BGLAP and IBSP, usually considered as characteristic of the osteoblastic phenotype and targets of RUNX2, was also increased in hMSCs from fracture patients in basal conditions. However, those hMSCs showed a reduced ability to from a mineralized matrix when cultured in osteogenic medium. This could be related to a decreased activity of alkaline phosphatase, which plays a critical role in mineralization, or to the persistent up-regulation of RUNX2. RUNX2 is a master driver of osteoblast precursor differentiation 21 . Specific epigenetic marks contribute to the regulation of RUNX2 expression 22 . RUNX2 controls bone development and osteoblast differentiation by regulating the expression of a significant number of bone-related target genes, including collagen, osteocalcin, osteopontin, bone sialoprotein and osteoprotegerin. Thus, it plays a critical role in the early stages of differentiation of hMSCs into pre-osteoblasts. However, after this initial step, RUNX2 expression must be turned down to allow terminal differentiation of osteoblasts 23 .
11
Recent experiments in rodent models of osteoporosis have shown that the MSC transplantation may have a positive effect on bone mass locally and even systemically 24, 25 . Additionally, molecules helping to target deliver MSCs into bone are being developed 26 . This raises the possibility of using MSCs for bone regeneration, fracture consolidation or treating widespread bone loss. Since allogenic transplants of MSCs pose difficulties related to histocompatibility, in clinical practice autologous transplants would be preferable. In this line, our results are encouraging because they show that, despite some accelerated epigenetic aging, hMSCs from patients with fragility fractures are activated and maintain a good proliferation capacity, rendering them potentially useful for autologous transplants. Indeed, these cells were able to express genes encoding several proteins present in bone matrix in quantities similar to those expressed by cells from OA patients, which have been reported to behave similarly to MSCs from healthy subjects 9 . However, their ability for terminal differentiation and the formation of a mineralized matrix appear to be compromised, at least in vitro. Hence, it would be highly desirable to reach a better understanding of the mechanisms impairing that ability in order to circumvent them with the final objective of optimizing bone matrix formation in vivo.
In summary, the epigenome-wide signature of hMSCs from fracture patients shows differentially methylated regions in comparison with hMSCs derived from OA patients. Most differences are in genomic regions with enhancer activity, distant from gene bodies and apart from CpG islands. They are associated with up-regulation of a number of genes involved in MSC proliferation and differentiation, including an up-regulation of genes such as RUNX2/OSX driving the differentiation towards an osteoblastic phenotype. However, their ability to form a mineralized matrix appears to be impaired. These results point to two areas of potential interest for discovering new therapeutic targets for low bone mass disorders and bone regeneration: the mechanisms stimulating MSCs after fracture and the mechanisms impairing the terminal differentiation of MSCs. Additionally, these results emphasize the concept that modifications of DNA methylation may have a cis-influence on rather distant genes.
MATERIALS AND METHODS
Human Mesenchymal Stem Cells (hMSCs) isolation and culture
Bone marrow hMSCs were obtained from the femoral heads of patients undergoing replacement surgery due to osteoporotic hip fractures (FRX; n=25, age 62 to 88 yrs) or hip osteoarthritis (OA; n=17, age: 72 to 92 yrs). They included female patients with osteoporotic hip fractures or hip osteoarthritis. Patients with high-impact fractures, secondary osteoporosis or secondary OA were excluded. All patients gave informed written consent. The study protocol was approved by the institutional review board (Comité de Etica en Investigación Clínica de Cantabria). Cylinders of trabecular bone were extracted with a trephine, after removing the subchondral and subfracture edges, they were washed with 50 mL of phosphate-buffered saline (PBS). Cells were subjected to a density Raw data files were pre-processed using R/Bioconductor package RnBeads, 27 and methylation was described as β value, which ranges between 0 (no methylation) to 1 (full methylation).Analyses were conducted at the single CpG site level and at various region levels, including age as a covariate.
Regions with FDR<0.05 and an absolute difference in methylation higher than 10% (Δβ>0.10) were considered as differentially methylated. Annotation data for the genomic enhancers' study were retrieved from the H1 embryonic stem cell line from the UCSC Table Browser. The methylation level of selected CpGs was replicated by pyrosequencing (PyromarkQ24 Advanced System®). Primers used for PCR amplification and sequencing were designed with the PyroMark assay designer (Supplemental Table S5 ). The statistical significance of the differences between FRX and OA patients was tested by Mann-Whitney tests, with a significance threshold of 0.05.
Transcriptome analysis
RNA was isolated from hMSCs (n=10 FRX and n=10 OA) using Trizol® (Thermofisher Scientific, Waltham, MA, USA). After quality check and quantitation, the samples were prepared using the NEBNext Ultra Directional RNA Library Protocol. Samples were sequenced on an Illumina Hi-seq 2000 sequencer (NTX-Dx, Gent, Belgium). Sample reads were mapped to the human reference genome build GRCh37. Expression analysis was done with cufflinks v2. RNAseq data and expression of selected genes were confirmed by using real-time quantitative PCR (qPCR), after reverse-transcription of RNA into cDNA, using the housekeeping genes GAPDH and RPL13A for normalization. Assay details are given in Supplemental Table S5 .
DNA methylation age
The epigenetic age was calculated from the methylation level of a set of 353 CpGs which has been shown to change with aging in a wide variety of tissues 33 . The relationship of the epigenetic age and the chronological age was explored by linear regression analysis.
Proliferation Analysis
The proliferation status of hMSCs was assessed by immunocytochemistry using an anti-Ki-67 antibody, a nuclear protein associated with cell proliferation. The results were confirmed by a cell proliferation colorimetric assay based on the reduction of the tetrazolium dye MTT. 15 hMSCs were cultured in osteogenic induction medium (low glucose Dulbecco Modified Eagle Medium (DMEM) with 10% FBS, 50 µM ascorbic acid, 10 mM β-glycerophosphate, 100 nM dexamethasone) or adipogenic induction medium (DMEM, supplemented with 1.0 M dexamethasone, 0.2 mM indomethacin, 0.5 mM 3-isobutyl-1-methylxanthine, 10% FBS). hMSCs were plated in a 24 wells plate and incubated for up to 3 weeks, prior to staining or RNA extraction. The formation of mineralized matrix was assessed by Alizarin Red staining. The staining was evaluated semiquantitatively by two independent observers who were blind of the culture origin. Other wells were used to determine alkaline phosphatase activity in cell lysates by a colorimetric method based on the ability of ALPL to hydrolyze p-nitrophenylphosphate, 34 . Oil Red was used to visualize the presence of lipid droplets.
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